BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37932179)

  • 1. Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer.
    Yu Lee-Mateus A; Sawal N; Hartley C; Edell E; Vierkant RA; Reisenauer J
    Clin Lung Cancer; 2024 Jan; 25(1):e11-e17. PubMed ID: 37932179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of shape-sensing robotic-assisted bronchoscopy for biomarker identification in patients with thoracic malignancies.
    Connolly JG; Kalchiem-Dekel O; Tan KS; Dycoco J; Chawla M; Rocco G; Park BJ; Lee RP; Beattie JA; Solomon SB; Ziv E; Adusumilli PS; Buonocore DJ; Husta BC; Jones DR; Baine MK; Bott MJ
    J Thorac Cardiovasc Surg; 2023 Jul; 166(1):231-240.e2. PubMed ID: 36621452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
    BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.
    Vannitamby A; Hendry S; Makadia T; Danks J; Slavin J; Irving L; Steinfort D; Bozinovski S
    J Mol Diagn; 2019 Mar; 21(2):186-197. PubMed ID: 30772141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Stoy SP; Rosen L; Mueller J; Murgu S
    Cancer Cytopathol; 2018 Feb; 126(2):122-128. PubMed ID: 29053224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
    Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
    Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
    Biswas A; Leon ME; Drew P; Fernandez-Bussy S; Furtado LV; Jantz MA; Mehta HJ
    Diagn Cytopathol; 2018 May; 46(5):378-383. PubMed ID: 29476608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.
    Satturwar S; Girolami I; Munari E; Ciompi F; Eccher A; Pantanowitz L
    Diagn Cytopathol; 2022 Jun; 50(6):313-323. PubMed ID: 35293692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 (22C3) Expression Correlates with Clinical and Molecular Features of Lung Adenocarcinomas in Cytological Samples.
    Anderson SA; Harbi D; Oramas Mogrovejo D; Floyd AD; Eltoum IE; Fatima H; Rosenblum F; Lora Gonzalez M; Lin D; Mackinnon AC; Siegal GP; Winokur T; Yalniz C; Huo L; Harada S; Huang X
    Acta Cytol; 2023; 67(5):507-518. PubMed ID: 37494911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer.
    Fu F; Deng C; Sun W; Zheng Q; Jin Y; Li Y; Zhang Y; Chen H
    Respir Res; 2022 Nov; 23(1):302. PubMed ID: 36335353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
    Bozzetti C; Squadrilli A; Nizzoli R; Lagrasta C; Gasparro D; Majori M; Filippo M; Becchi G; Azzoni C; Campanini N; Pedrazzi G; Zavani A; Silini EM; Tiseo M; Gnetti L
    Immunotherapy; 2020 Feb; 12(3):183-193. PubMed ID: 32066299
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
    Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
    Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.